Sangamo BioSciences Reports Third Quarter 2008 Financi...(nd administrative expenses were $2.6 mil...)

Date:10/29/2008

nd administrative expenses were $2.6 million for the third quarter of 2008, compared to $1.7 million for the same period in 2007. The increase in general and administrative expenses was primarily due to increased personnel costs, including non-cash stock-based compensation which totaled $709,000 in the third quarter of 2008 compared to $202,000 in the same period in 2007.

Total operating expenses for the third quarter of 2008 were $10.1 million, compared to $7.6 million for the same period in 2007.

Net interest and other income was $42,000 for the third quarter of 2008, compared to $1.1 million for the same period in 2007. The decrease is due to lower average investment balances and lower interest rates as well as a foreign currency translation loss during the quarter.

Nine Month Results

For the nine months ended September 30, 2008, the consolidated net loss was $21.7 million, or $0.53 per share, compared to a net loss of $14.8 million, or $0.41 per share, for the nine-month period ended September 30, 2007. Revenues were $9.4 million for the first nine months of 2008, compared to $6.3 million in the same period in 2007. Total operating expenses were $32.5 million for the first nine months of 2008 and $23.5 million for the same period of 2007. The increase in operating expenses for 2008 was primarily associated with Sangamo's clinical development programs in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and glioblastoma, as well as increased research and development personnel costs and lab supply expenses.

Recent Highlights

* Initiation of a Phase 2 clinical trial (SB-509-801) to evaluate SB-509

in subjects with Amyotrophic Lateral Sclerosis (ALS). ALS is a

progressive, degenerative motor-neuron disease for which there are

limited treatment options and no cure. The Phase 2 trial is a

randomized repeat-dosing, open-label, multi-cen
'/>"/>

SOURCE Sangamo BioSciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
2. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
3. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
4. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
5. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
6. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
7. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
8. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
9. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
10. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
11. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration